Skip to content
value.today
Longeveron Inc. logo

Longeveron Inc.

LGVN
$24 Mmarket cap on Aug 1, 2026-27.3% since Jan 2024
Compare
World rank
#23,744
Revenue
$1 M
For year ending December-2025
Net income
$-23 M
-1891.7% margin
SEC filing
Employees
37
As of December 31, 2025
SEC filing

Longeveron Inc. in brief

Longeveron Inc. is a listed company in the Biotechnology industry, based in Miami, Florida, USA. It was founded in 2014. Its market value was $24 M on 1 August 2026, which makes it the 23,744th largest listed company in the world and the 4,100th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $23 M. It employs about 37 people and Stephen H. Willard is its chief executive. Its largest product and service lines by sales in 2025 were Clinical trial revenue (80%), Contract manufacturing revenue (19%) and Contract manufacturing lease revenue (2%). Its shares trade under the symbol LGVN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Longeveron Inc.

We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas. Our mission is to continue to advance the development and regulatory approval of laromestrocel in order to make it available for patients who may need it.

From the company's annual report filed with the US SEC: read the report

Longeveron Inc. timeline

4 events, 2014–2021
  1. 2014
  2. 🏁
    · approximate
    Founded
  3. 2017
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. ✎
    Renamed Longeveron Inc.
    Formerly Longeveron Llc.
  7. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 February 2021; shares registered for exchange trading on 11 February 2021.

Events of Longeveron Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$55 M$109 M$164 M$218 M2023202420252026

World rank over time

▼ down 2,212 places since 2022
2022-01-07: #19174#19,17420222022-12-25: #23539#23,53920222023-07-30: #23513#23,51320232024-01-05: #26861#26,86120242026-03-08: #12746#12,74620262026-08-01: #21386#21,3862026

Rank in USA: #3,827 (Jan 2022) · #4,557 (Dec 2022) · #4,506 (Jul 2023) · #4,232 (Jan 2024) · #2,378 (Mar 2026) · #3,912 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
20.5×
Price / book
4.2×
Free cash flow yield
-78.7%
Net margin (TTM)
-1913.7%
Operating margin
-1940.8%
Return on equity
-394.2%
Liabilities / assets
44.7%
Net debt
$-1M
Revenue growth
-49.8%
R&D / revenue
1003.3%
Revenue per employee
$32 K
Profit per employee
$-614 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $6M, net income $-4M$6MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-17M$1MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-19M$1MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-21M$1MFY23Fiscal year ending Dec 2024: revenue $2M, net income $-16M$2MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-23M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M-49.8%$-23M$-23M-1891.7%
Dec 2024$2M+236.6%$-17M$-16M-668.2%
Dec 2023$1M-41.8%$-21M$-21M-3015.5%
Dec 2022$1M-6.9%$-18M$-19M-1544.3%
Dec 2021$1M-76.7%$-17M$-17M-1300.8%
Dec 2020$6M—$-4M$-4M-66.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-19M$0M$-19M$-1.29—
Dec 2024$-14M$1M$-15M$-2.62—
Dec 2023$-19M$0M$-19M$-10.22—
Dec 2022$-14M$1M$-15M$-0.90—
Dec 2021$-10M$0M$-10M$-0.90—
Dec 2020$-2M$0M$-2M$-0.23—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$1M
Net income, trailing 12 months
$-22M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-4M$1MDec ’24Three months to Mar 2025: revenue $0M, net income $-5M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-5M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-7M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-5M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-5M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-6M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-6M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (-14.3% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Longeveron Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-23 M
Net income
$-23 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$5 M
Total equity
$6 M

As of December-2025

Top 18 institutional investors in Longeveron Inc.#

As of Sep 30, 2026
18 institutions held 494,558 shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 18 largest institutional investors in Longeveron Inc.
#InstitutionShares heldChange (shares)ValueFiled
1Logos Global Management LP192,308New$1 MNov 16, 2026
2Janus Henderson Group Ltd.128,699—$0 MNov 16, 2026
3Vanguard Capital Management LLC72,787New$0 MNov 13, 2026
4Geode Capital Management, LLC25,119New$0 MNov 6, 2026
5BlackRock, Inc.22,416New$0 MNov 13, 2026
6HRT Financial LP15,294New$0 MNov 13, 2026
7Vanguard Fiduciary Trust Co14,012New$0 MNov 13, 2026
8ADAR1 Capital Management, LLC10,840New$0 MNov 16, 2026
9Beacon Pointe Advisors, LLC10,000New$0 MNov 16, 2026
10Tower Research Capital LLC (TRC)2,101New$0 MNov 16, 2026
11Jones Financial Companies Lllp300New$0 MNov 13, 2026
12Steward Partners Investment Advisory, LLC238New$0 MNov 13, 2026
13SBI Securities Co., Ltd.226New$0 MOct 22, 2026
14Osaic Holdings, Inc.200New$0 MNov 12, 2026
15Allworth Financial LP13New$0 MNov 17, 2026
16FMR LLC2New$0 MNov 10, 2026
17UBS Group AG2New$0 MNov 10, 2026
18Danske Bank A/s1New$0 MNov 9, 2026

Mutual funds holding Longeveron Inc.#

6 funds hold shares worth $1 M. Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Longeveron Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.361,300$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.180,732$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC116,119$0 M—<0.01%+63%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC23,926$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC20,397$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,931$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Longeveron Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
30
since
$450 K-$37 K$0Dec 2023: bought $28 K (3 trades), sold $0 (0 trades)Dec 23Jan 2024: bought $7 K (1 trades), sold $0 (0 trades)Jan 24Apr 2024: bought $450 K (5 trades), sold $0 (0 trades)AprDec 2024: bought $0 (0 trades), sold $3 K (1 trades)DecMay 2025: bought $0 (0 trades), sold $37 K (4 trades)MayAug 2025: bought $0 (2 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Longeveron Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Devin BlassCTO & SVP of CMCShares withheld for tax-2,520$2.590$7 K68,653Form 4
filed Paul T. LehrGeneral Counsel, SecretaryShares withheld for tax-2,253$2.590$6 K83,889Form 4
filed Nataliya AgafonovaChief Medical OfficerShares withheld for tax-2,913$2.590$8 K68,778Form 4
filed Stephen H. WillardChief Executive OfficerShares withheld for tax-1,987$2.590$5 K74,916Form 4
filed Nirav S. JhaveriChief Financial OfficerShares withheld for tax-742$2.590$2 K29,258Form 4
filed Leah Rush CannDirectorGrant or award+36,000——36,000Form 4
filed Deborah AscheimDirectorGrant or award+36,000——36,000Form 4
filed Nataliya AgafonovaChief Medical OfficerGrant or award+286,000——716,914Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Longeveron Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
157,139
2.18 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-09-16 20:55 UTC, code T3, resumed 21:55 UTC
  • 2026-08-26 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-08-08 17:29 UTC, code LUDP, resumed 17:34 UTC

Fails to deliver

  • : 11,542 shares at $1.73
  • : 11,493 shares at $1.59
  • : 1,007 shares at $1.50
  • : 5,623 shares at $2.45
  • : 1,226 shares at $2.44

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Longeveron Inc. scorecard#

Passes 1 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-49.8%Revenue down 49.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-0.6%-0.6% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-0.6%-0.6% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.29 vs -2.62Diluted EPS -1.29 in fiscal 2025 against -2.62 the year before (report's currency).
    • ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$4 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-164.7%-164.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.33 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-22.13Z-score -22.13 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year86.8%Diluted shares up 86.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Longeveron Inc.'s statements, beside the median of Biotechnology.

Longeveron Inc.: main financial ratios in 2025
Ratio2025Median of peers
Return on equity-164.7%-61.0%
Revenue growth, 3 years a year-0.6%12.9%
Revenue growth-49.8%15.8%

2of 8on the Piotroski tests of financial strength

  • Revenue fell 49.8% against the year before.
  • Net loss of $23 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$19 million.
  • The share count rose 86.8% in the year.

Longeveron Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Longeveron Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue1.22.40.71.21.35.6
Cost of revenue0.40.50.50.70.73.8
Gross profit0.81.90.20.50.61.8
Research and development128.19.19.47.12.7
Selling and marketing——0.81.11.2r0.2
General and administrative121012r8.19.7r2.7
Operating expenses24182119185.6
Operating income−23−17−21−18−17−3.8
Interest expense and finance costs———1.40.00.0
Other non-operating income (expense)0.60.5−0.4−0.80.40.1
Income tax0000——
Net income including minority interests————−17−3.7
Net income attributable to shareholders−23−16−21−19−17−3.7
Earnings per share, basic-1.29-2.62-10.22r-0.90-0.90-0.23
Earnings per share, diluted-1.29-2.62-10.22r-0.90-0.90-0.23
Shares, weighted average (basic)17,5779,4112,173r2119—
Shares, weighted average (diluted)17,5779,4112,173r211916
Balance sheet
Cash and cash equivalents4.7194.911260.8
Short-term investments—00.49.29.5—
Receivables0.10.10.10.20.1—
Other current assets0.70.30.40.40.30.1
Current assets5.5205.82035r1.8
Property, plant and equipment1.82.42.52.93.13.6
Right-of-use (leased) assets0.50.91.21.51.8r2.1
Other intangible assets2.32.42.32.42.31.5
Total assets10261227439.2
Accounts payable0.40.10.61.80.61.6
Debt due within a year—————0.1r
Current liabilities4.12.63.94.92.73.8
Lease liabilities (non-current)0.20.81.42.0——
Non-current liabilities0.51.11.42.0——
Total liabilities4.63.75.36.95.37.3
Retained earnings−132−110−85−63−44—
Shareholders' equity5.7226.721372.0r
Total liabilities and equity10261227439.2
Cash-flow statement
Depreciation and amortization0.80.70.70.7r0.00.0
Share-based compensation1.72.32.02.2r1.30.0
Cash from operating activities−19−14−19−14−9.6−2.4
Capital expenditure−0.2−0.7−0.3−0.6−0.3−0.1
Intangible assets bought−0.4−0.3−0.4−0.3−1.0−0.1
Cash from investing activities−0.6−0.68.2−0.7−11−0.3
Debt issued—————0.5
Shares issued5.0135.30.027—
Cash from financing activities4.7295.3−0.5451.6
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Longeveron Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Clinical trial revenue$1 M80%
  • Contract manufacturing revenue$0 M19%
  • Contract manufacturing lease revenue$0 M1.9%

Business segments

  • Reportable$1 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Longeveron Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 13 · Material agreement 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 3 · Shareholder vote 1 · Results announced 5

Longeveron Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Delisting noticeDirectors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Longeveron Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$16 MPrivate placement after listing$10 to $50 million7equity, optionsSEC
Dec 2021$20 MNo. 1$10 to $50 million20equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Longeveron Inc. compares in Biotechnology

  • Market cap$24 M · higher than 19% of 726
  • Revenue$1 M · higher than 26% of 647
  • Revenue growth-49.8% · higher than 19% of 438
  • Price / sales20.5× · lower than 31% of 339
  • Price / book4.2× · lower than 37% of 534
  • FCF yield-78.7% · higher than 13% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Longeveron Inc.🇺🇸$24 M——-49.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Longeveron Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Longeveron Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Longeveron Inc.? Suggest a correction